Literature DB >> 16877660

Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study.

Diederik E Tenback1, Peter N van Harten, Cees J Slooff, Jim van Os.   

Abstract

OBJECTIVE: This study examined whether extrapyramidal symptoms predict incidence of tardive dyskinesia 1 year later.
METHOD: Simple, global measures were used to rate extrapyramidal symptoms and tardive dyskinesia in a prospective, observational health outcomes study. Baseline and 3-, 6-, and 12-month data on 9,298 patients were analyzed by using a Cox proportional-hazard model. Onset of tardive dyskinesia was examined in two groups: 1) no tardive dyskinesia at baseline (broad risk set) and 2) no tardive dyskinesia at baseline and 3 months (narrow risk set).
RESULTS: Baseline extrapyramidal symptoms predicted later onset of tardive dyskinesia (broad risk set: hazard ratio=2.0, narrow risk set: hazard ratio=1.6). In analyses adjusted for age, gender, and medication exposure, this effect size was not reduced. About half of patients who developed tardive dyskinesia had earlier extrapyramidal symptoms.
CONCLUSIONS: Although the association of tardive dyskinesia and extrapyramidal symptoms is significant, extrapyramidal symptoms do not robustly identify individuals at high risk for tardive dyskinesia. However, drug regimens and disease processes that increase extrapyramidal symptoms are likely to result in increased risk of tardive dyskinesia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16877660     DOI: 10.1176/ajp.2006.163.8.1438

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  21 in total

Review 1.  Comparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us?

Authors:  Azizah Attard; David M Taylor
Journal:  CNS Drugs       Date:  2012-06-01       Impact factor: 5.749

2.  Association of the ZFPM2 gene with antipsychotic-induced parkinsonism in schizophrenia patients.

Authors:  Lior Greenbaum; Robert C Smith; Mordechai Lorberboym; Anna Alkelai; Polina Zozulinsky; Tzuri Lifschytz; Tzuri Lifshytz; Yoav Kohn; Ruth Djaldetti; Bernard Lerer
Journal:  Psychopharmacology (Berl)       Date:  2011-09-24       Impact factor: 4.530

3.  Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients.

Authors:  Jeroen P Koning; Jelle Vehof; Huibert Burger; Bob Wilffert; Asmar Al Hadithy; Behrooz Alizadeh; Peter N van Harten; Harold Snieder
Journal:  Psychopharmacology (Berl)       Date:  2011-07-13       Impact factor: 4.530

4.  Management of common adverse effects of antipsychotic medications.

Authors:  T Scott Stroup; Neil Gray
Journal:  World Psychiatry       Date:  2018-10       Impact factor: 49.548

Review 5.  Tardive Dyskinesia Associated with Atypical Antipsychotics: Prevalence, Mechanisms and Management Strategies.

Authors:  Katharina Stegmayer; Sebastian Walther; Peter van Harten
Journal:  CNS Drugs       Date:  2018-02       Impact factor: 5.749

Review 6.  Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons.

Authors:  Christine Rummel-Kluge; Katja Komossa; Sandra Schwarz; Heike Hunger; Franziska Schmid; Werner Kissling; John M Davis; Stefan Leucht
Journal:  Schizophr Bull       Date:  2010-05-31       Impact factor: 9.306

7.  Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients.

Authors:  Arzu Gunes; Marja-Liisa Dahl; Edoardo Spina; Maria Gabriella Scordo
Journal:  Eur J Clin Pharmacol       Date:  2008-01-18       Impact factor: 2.953

Review 8.  Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review.

Authors:  Keming Gao; David E Kemp; Stephen J Ganocy; Prashant Gajwani; Guohua Xia; Joseph R Calabrese
Journal:  J Clin Psychopharmacol       Date:  2008-04       Impact factor: 3.153

9.  Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.

Authors:  Hoda Moteshafi; Simon Zhornitsky; Sarah Brunelle; Emmanuel Stip
Journal:  Drug Saf       Date:  2012-10-01       Impact factor: 5.606

10.  Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients.

Authors:  Ana Alkelai; Lior Greenbaum; Amihai Rigbi; Kyra Kanyas; Bernard Lerer
Journal:  Psychopharmacology (Berl)       Date:  2009-08-13       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.